Clinical Trial Update: Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nifurtimox for refractory or relapsed neuroblastoma or medulloblastoma has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Neuroblastoma

Drugs mentioned

• Nifurtimox (Nifurtimox)

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma, Medulloblastoma | Phase 2 | Status: COMPLETED | Results posted: 2022-12-29